Galderma will share exciting phase III data on its novel, investigational, ready-to-use liquid botulinum toxin A, RelabotulinumtoxinA, further reinforcing its unprecedented efficacy and safety in treating frown lines and crow’s feet.1-3
Two symposia will educate on individualized treatment approaches by exploring the aesthetic lives of patients and the science behind our products, using the AART methodology; and our first Medical Affairs symposium will focus on skin science.
The company will present 10 research posters in total, including new data on Sculptra as we proudly celebrate its 25th anniversary.
ZUG, Switzerland--(BUSINESS WIRE)--Galderma will be sharing the latest updates from across its broad and unparalleled portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2024 from February 1-3, 2024, in Paris. The updates reinforce Galderma’s leadership in aesthetic injectables and dermatological skincare. In addition to presenting 10 research posters highlighting data from across the portfolio —including on our investigational neuromodulator RelabotulinumtoxinA — Galderma will host a number of events dedicated to addressing the real needs of physicians. This will include three symposia and several ‘Meet the Expert’ and interactive booth sessions.
|
“The breadth of our data and activities at IMCAS truly embodies our commitment to responding directly to the needs of healthcare professionals and patients. We’re looking forward to another opportunity to listen and learn from the aesthetics community to help us further advance our groundbreaking innovations.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF R&D
GALDERMA
|
|网站首页|财经金融|银行|股票|基金|保险|期货|股评|港股|美股|外汇|债券|黄金|理财|信托|房产|汽车|
|